Last reviewed · How we verify
Omega-3 polyunsaturated fatty acids
At a glance
| Generic name | Omega-3 polyunsaturated fatty acids |
|---|---|
| Also known as | Docosahexaenoic Acid (DHA)/Eicosapentaenoic Acid (EPA), omega-3 PUFA, ω-3 PUFA |
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction (PHASE2)
- Omega-3 Supplementation vs Demodex vs Eyelid Cleanser for Pediatric Chalazia (PHASE2)
- FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM) (PHASE2)
- Heart & Health Study (NA)
- NMDA Enhancement Combined With Omega-3 for Early Dementia (PHASE2)
- A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth (PHASE4)
- Can People Achieve a Target Omega-3 Index by Following a Personalized Omega-3 Dosing Regimen? (NA)
- Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omega-3 polyunsaturated fatty acids CI brief — competitive landscape report
- Omega-3 polyunsaturated fatty acids updates RSS · CI watch RSS
- Mayo Clinic portfolio CI